Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

for walking Responders compared to Non-responders (p less than 0.001). In addition, the mean scores on all 12 questions in the MSWS-12 were better for the Responder group than the Non-responder group.

Subject Global Impression and Clinician Global Impression scales were used as secondary validators of clinical meaningfulness. Both measures also showed statistically significant improvement among Responders compared to Non-responders (p = 0.0010 and p less than 0.0001, respectively).

Statistically significant increases in leg strength, as measured by the Lower Extremity Manual Muscle Test (LEMMT), were seen in both the drug-treated Timed Walk Responders (p = 0.0002) and the drug-treated Non-responders (p = 0.046), compared to placebo-treated patients.

In an unplanned, direct comparison of Fampridine-SR vs. placebo-treated groups, the following measures were significantly improved in the Fampridine-SR-treated group: mean change in walking speed (p = 0.0004), mean change in the Lower Extremity Manual Muscle Test (p = 0.0029), and mean change in the Ashworth score for spasticity (p = 0.021).

Andrew Blight, Ph.D, Chief Scientific Officer of Acorda Therapeutics, commented, "Walking impairment is one of the most pervasive and serious disabilities afflicting people with MS, and there are no currently approved therapies that are indicated to improve walking in this population. Fampridine-SR, if approved, may offer a novel treatment for improving walking ability in people with MS, one that may be complementary to currently available therapies. In this study, we also saw improvements in measures of leg strength and spasticity compared to the placebo group. In particular, even the Fampridine-SR group that did not show a consistent walking improvement still showed a statistically significant improvement in leg strength compared to the placebo group. Further clinical studies would be required to determine whether such additional improvements may be cli
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:7/29/2014)... July 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... candidates targeting specific pathogens that cause serious infections and ... market activity in the Company,s stock, the NYSE MKT ... its usual practice. The Company stated that its policy ... About Synthetic Biologics, Inc. Synthetic Biologics, ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... , DUBLIN, Ohio, Dec. 2 Cardinal Health today announced ... directors, effective immediately. , Cox, 52, most recently served as ... Corp. She completed her tenure with the company at the ... Prior to her term at Schering-Plough, Cox served as president ...
... , , ROCKVILLE, Md., Dec. 2 ... results from the first stage of a two-stage pivotal Phase ... 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax ... Mexico to support registration of the vaccine in Mexico and ...
Cached Medicine Technology:Cardinal Health Names Carrie Cox to Board of Directors 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... 29, 2014 The Law Offices of Michael ... of Hope, a non-profit organization providing grief camps for kids, ... anguish and suffering our clients experience from the death of ... support an organization like Stepping Stones of Hope, as they ... Stepping Stones of Hope also includes a monthly support group ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 During his 37 ... Bruce, DMD & Associates, has had a steady stream of ... dentistry. These students have now gone on to dental school ... proving that the shadowing program helps college students find success. ... Bruce has given them the chance to see a realistic ...
(Date:7/29/2014)... July 29, 2014 Summer is here, and that ... enjoying a hike, swimming in a pool or laying out on ... fleas and ticks. The Puppy Store is here to help pet ... months. , It’s almost impossible to completely keep fleas and ticks ... minimize the chances of their pets coming into contact with fleas ...
(Date:7/29/2014)... receive steady follow-up care, the living donors themselves ... care more accessible, UC San Francisco and Walgreens ... the first program in the country that provides ... kidney donors. , UCSF will provide vouchers for ... Walgreens pharmacies and Healthcare Clinic at select Walgreens ...
Breaking Medicine News(10 mins):Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Caring for donors 2Health News:Caring for donors 3
... seeks insights into chronic, illnesses, including heart failure and COPD, ... ... VENTURA, Calif., Oct. 8 VivoMetrics announced today,that noted researcher Bruce D. ... VivoMetrics LifeShirt(R) System to,the South Pole to collect valuable data for his ...
... Oct. 8 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ... as,senior vice president and chief commercial officer, effective ... NPS executive team, Mr. O,Callaghan will be,responsible for ... activities, including the commercial development of NPS,s,late-stage products ...
... The Physicians Coalition,for Injectable Safety today issued ... lipolysis or other injectable treatments touted to,reduce localized ... not,be mistaken as an accepted medical or cosmetic ... fat, using compounded pharmaceuticals, or,herbal agents, claim a ...
... the stories of eight mothers who survived ... breast ... product and baby gear brand, celebrates the "Power of Pink" by,announcing the ... Month, the eight outstanding women will be recognized,during the Susan G. Komen ...
... NEW YORK, Oct. 8 Health Management Systems,Inc. ... business of Peer Review,Systems, Inc. d/b/a/ Permedion, an ... in Westerville, Ohio. With this,acquisition, HMS augments its ... offerings for state Medicaid agencies and,managed care organizations. ...
... likely than whites to get tamoxifen, for example , , MONDAY, ... that has spread to the lymph nodes are less likely ... chemotherapy than white women with the same level of disease ... to the lymph nodes, we are seeing that African-American women ...
Cached Medicine News:Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 2Health News:VivoMetrics' LifeShirt Going to South Pole to Uncover Clues to High-Altitude Illness 3Health News:NPS Pharmaceuticals Names Brian O'Callaghan as New Chief Commercial Officer 2Health News:Consumer Safety Alert on Fat Dissolving Injections 2Health News:Consumer Safety Alert on Fat Dissolving Injections 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 2Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 3Health News:'Pink Power Moms' Unite in Atlanta for Day of Pampering and Recognition 4Health News:HMS Acquires Permedion to Expand Clinical Review Capabilities 2Health News:Black Women Get Less Breast Cancer Treatment 2Health News:Black Women Get Less Breast Cancer Treatment 3
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: